Peking University Medicine: The company does not have an innovative drug business, mainly engaged in the research, production, and sales of generic drugs.

（Source: Caixin）

          The company’s stock closing price increased by a cumulative amount of deviation of over 20% within two consecutive trading days. According to the relevant regulations of the Shenzhen Stock Exchange, this situation falls under abnormal stock trading fluctuations.            

April 2, Peking University Health (000788.SZ) released an announcement regarding abnormal stock trading fluctuations. The company’s stock closing price increased by a cumulative amount of deviation of over 20% within two consecutive trading days. According to the relevant regulations of the Shenzhen Stock Exchange, this situation falls under abnormal stock trading fluctuations.

In response to the company’s abnormal stock trading fluctuations, the company conducted an investigation into the relevant matters and questioned the company’s controlling shareholder. After verification, as of the date of disclosure of this announcement, there are no matters requiring correction or supplementation regarding the information previously disclosed by the company; the company has not found any undisclosed material information in recent public media reports that could or has already had a significant impact on the company’s stock trading price; the company’s production and operating conditions are normal, and there has been no major change in the internal or external business environment; the company’s controlling shareholder does not have any other major matters regarding the company that should be disclosed but have not been disclosed, nor does it have any major matters involving the company currently in the planning stage; during the period of abnormal stock fluctuations, the company’s controlling shareholder, Xinan Synthetic Pharmaceutical Group Co., Ltd., has not engaged in buying or selling the company’s stock; the company’s second-largest shareholder, Neidai Medical Management Co., Ltd., is still in the stage of implementing the previously disclosed reduction plan; the company does not have an innovative drug business. It mainly engages in the research, production, and sales of chemical drug formulations (generic drug formulations). Its main products cover fields such as “anti-infection, analgesics, psychiatry, and chronic diseases.”

Meanwhile, the company reminds investors to pay attention to the relevant risks: the company’s chairman and president are temporarily unable to perform their duties because their arrest has been approved by the Jiangbei District People’s Procuratorate in Chongqing, and the company has authorized relevant personnel to carry out the duties of the chairman, president, and legal representative on their behalf; the company disclosed the “2025 Annual Performance Forecast” on January 30, 2026. As of the date of disclosure of this announcement, there is no situation in which the company needs to revise its 2025 Annual Performance Forecast. The company’s 2025 annual report will be disclosed on April 28, 2026. Currently, the company is conducting audit-related work for the 2025 year, and specific financial data will be detailedly disclosed in the 2025 annual report.

A large amount of information and precise interpretation are available on Sina Finance APP